Join
Live feed
·
PRReleasevia Quantisnow
Gilead Sciences Inc. logo
HOOKIPA Pharma Inc. logo

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

ByQuantisnow·Wall Street's wire, on your screen.
GILD· Gilead Sciences Inc.HOOK· HOOKIPA Pharma Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GILD (Gilead Sciences Inc.), HOOK (HOOKIPA Pharma Inc.) and more on Quantisnow.